Newsmeme!
Discover News you didn't know existed
BETHESDA, MD----Sucampo Pharmaceuticals, Inc. today announced that it has completed enrollment and initial dosing of patients in two pivotal phase 3 trials of lubiprostone for the treatment of Opioid-Induced Bowel Dysfunction .
No tags found at this time. Be the first to tag this news item, learn more.
No related imagery found.
Sucampo Completes Enrollment in Phase 3 Pivotal Studies of Oral ... - Businesswire.com
BETHESDA, MD--( BUSINESS WIRE )-- Sucampo Pharmaceuticals , Inc. (NASDAQ:SCMP) today announced that it has completed enrollment and initial dosing of patients in two pivotal phase 3 trials of lubiprostone for the treatment of Opioid-Induced Bowel ...
Sucampo Completes Enrollment in Phase 3 Pivotal Studies of Oral ... - PR Inside
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that it has completed enrollment and initial dosing of patients in two pivotal phase 3 trials of lubiprostone for the treatment of Opioid-Induced Bowel Dysfunction (OBD). "If lubiprostone is ...
None found at this time.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |